Cargando…

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial

Expressed by cancer stem cells of various epithelial cell origins and hepatocellular carcinoma (HCC), CD133 is an attractive therapeutic target for HCC. The marker CD133 is highly expressed in endothelial progenitor cells (EPC). EPCs circulate in increased numbers in the peripheral blood of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Hanren, Tong, Chuan, Shi, Daiwei, Chen, Meixia, Guo, Yelei, Chen, Deyun, Han, Xiao, Wang, Hua, Wang, Yao, Shen, Pingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714531/ https://www.ncbi.nlm.nih.gov/pubmed/33312759 http://dx.doi.org/10.1080/2162402X.2020.1846926

Ejemplares similares

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
por: Wang, Yao, et al.
Publicado: (2018)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
por: Song, Yanjing, et al.
Publicado: (2017)

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma
por: Mei, Qian, et al.
Publicado: (2015)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
por: Dai, Hanren, et al.
Publicado: (2015)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
por: Bueno, Clara, et al.
Publicado: (2019)

Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
por: Yang, Chaopin, et al.
Publicado: (2023)

Label-free quantitative proteomics of CD133-positive liver cancer stem cells
por: Tsai, Sheng-Ta, et al.
Publicado: (2012)

Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo
por: Wang, Hezhi, et al.
Publicado: (2020)

CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection
por: Yeh, Chau-Ting, et al.
Publicado: (2009)

CD133(+) cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2017)

Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122
por: Song, Kyoungsub, et al.
Publicado: (2015)

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production
por: Guo, Yelei, et al.
Publicado: (2023)

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients
por: Chen, Yao-Li, et al.
Publicado: (2017)

Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma
por: Zhang, Jie, et al.
Publicado: (2020)

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
por: Lin, Shi-Ming, et al.
Publicado: (2016)

Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
por: Zhu, Xuekai, et al.
Publicado: (2014)

Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
por: Guo, Yelei, et al.
Publicado: (2021)

Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3
por: Wang, Yawei, et al.
Publicado: (2019)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines
por: Wang, Jue, et al.
Publicado: (2017)

Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma
por: Song, Yeonhwa, et al.
Publicado: (2020)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop
por: Wang, Xiaofei, et al.
Publicado: (2018)

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
por: Feng, Kaichao, et al.
Publicado: (2017)

Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance
por: Ji, Hongyan, et al.
Publicado: (2017)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells
por: Song, Yeonhwa, et al.
Publicado: (2017)

SNP rs2240688 in CD133 gene on susceptibility and clinicopathological features of hepatocellular carcinoma
por: Pan, Xiaolan, et al.
Publicado: (2020)

Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells
por: Zhang, Zhe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o71pr671cc9h5dc742kq29j09j